MRC1 and vaginal cancer: When a variant in non-MMR genes was identified, 61.11% (77/126) corresponded to colorectal cancer, followed by endometrial cancer in 17.46% (22/126), ovarian cancer in 10.32% (13/126), breast cancer in 7.14% (9/126), and gastric and vaginal cancer in 1.59% (2/126 each); in addition, a variant was identified in cervical cancer (Table 2).